Meribank Biotech Balance Sheet Health
Financial Health criteria checks 2/6
Meribank Biotech has a total shareholder equity of NT$618.4M and total debt of NT$166.6M, which brings its debt-to-equity ratio to 26.9%. Its total assets and total liabilities are NT$1.2B and NT$602.5M respectively.
Key information
26.9%
Debt to equity ratio
NT$166.56m
Debt
| Interest coverage ratio | n/a |
| Cash | NT$165.77m |
| Equity | NT$618.44m |
| Total liabilities | NT$602.50m |
| Total assets | NT$1.22b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 4724's short term assets (NT$358.8M) exceed its short term liabilities (NT$133.9M).
Long Term Liabilities: 4724's short term assets (NT$358.8M) do not cover its long term liabilities (NT$468.6M).
Debt to Equity History and Analysis
Debt Level: 4724's net debt to equity ratio (0.1%) is considered satisfactory.
Reducing Debt: 4724's debt to equity ratio has increased from 0% to 26.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4724 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 4724 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 56.8% each year